Abstract Number: 690 • 2014 ACR/ARHP Annual Meeting
Lupus Patients Requiring First Corticosteroid Intervention Late in Disease Course – a Phenotypic Description
Background/Purpose The University of Toronto Lupus Clinic (UTLC) recently described the phenotype of a group of inception patients with SLE who remained naïve of corticosteroid…Abstract Number: 688 • 2014 ACR/ARHP Annual Meeting
Corticosteroids in Early Treatment Pathways in SLE
Background/Purpose: The treatment algorithm for patients with new onset systemic lupus erythematosus (SLE) is more variable than that for other rheumatic diseases (e.g. rheumatoid arthritis).…Abstract Number: 687 • 2014 ACR/ARHP Annual Meeting
Effect of Corticosteroid Use By Dose on the Risk of Developing Organ Damage over Time in Systemic Lupus Erythematosus—the Hopkins Lupus Cohort
Background/Purpose: Reduction of corticosteroid dose remains an important goal in the management of systemic lupus erythematosus (SLE). Current standard of care in SLE relies heavily…Abstract Number: 685 • 2014 ACR/ARHP Annual Meeting
Successful Withdrawal and Discontinuation of Immunosuppressants in Lupus Patients: Outcomes and Predictors
Background/Purpose: Physicians and patients (Pts) are hesitant to withdraw immunosuppressant (IS) in Pts in clinical remission as the consequences of this approach are unknown.…Abstract Number: 686 • 2014 ACR/ARHP Annual Meeting
Clinicians Approaches to the Management of Background Therapy in SLE Patients in Clinical Remission: Results of an International Survey
Background/Purpose: At present there is no consensus on what constitutes a remission in SLE. In particular it is not clear how background therapy should be…Abstract Number: 684 • 2014 ACR/ARHP Annual Meeting
Effects of Current Therapies for Lupus on Disease Activity and Renal Flares
Background/Purpose: A paucity of data exists that delineates the effect of current medications for lupus on disease activity and the propensity for renal flares in…Abstract Number: 683 • 2014 ACR/ARHP Annual Meeting
Impact of Lupus on Work Productivity in Patients and Caregivers: Findings from a Cross-Sectional Online Survey in the United States
Background/Purpose Lupus imposes a substantial burden on patients’ work productivity1; however, little is known about its impact on the work productivity of those caring for…Abstract Number: 682 • 2014 ACR/ARHP Annual Meeting
Impact of Patient’s Priorities on the Management of Systemic Lupus Erythematosus
Background/Purpose: Systemic Lupus Erythematosus (SLE) greatly reduces the quality of life (QoL) and satisfaction with life of affected patients. SLE patients can have numerous unmet…Abstract Number: 679 • 2014 ACR/ARHP Annual Meeting
Hydroxychloroquine Dosing and Disease Activity in a Large Multi-Racial Lupus Cohort
Background/Purpose: Treatment with hydroxychloroquine (HCQ) is recommended for all patients with lupus nephritis to prevent further damage and reduce disease manifestations. Some studies suggest…Abstract Number: 678 • 2014 ACR/ARHP Annual Meeting
The Effectiveness of Tacrolimus for Minor Flares of the Patients with Systemic Lupus Erythematosus
Background/Purpose Although effectiveness of tacrolimus (TAC) for remission induction or maintenance treatment of patients with lupus nephritis has been reported, there are few reports about…Abstract Number: 677 • 2014 ACR/ARHP Annual Meeting
Pharmacokinetics, Safety, and Biological Activity of Intravenously or Subcutaneously Administered Tabalumab in Subjects with Rheumatoid Arthritis or Systemic Lupus Erythematosus
Background/Purpose : B-cell activating factor (BAFF) promotes B-cell survival and maturation, and increased serum levels are associated with autoimmune disease and disease activity in systemic…Abstract Number: 676 • 2014 ACR/ARHP Annual Meeting
Response to Rituximab in Patients with Refractory Systemic Lupus Erythematosus (SLE): Results from a National Multicentre Register
Background/Purpose: Published efficacy data for rituximab in SLE are complex with positive single-centre case series and negative randomised controlled trials. This may be due to…Abstract Number: 675 • 2014 ACR/ARHP Annual Meeting
Use of Rituximab in Systemic Lupus Erythematosus: A Single Center Experience
Background/Purpose Rituximab (RTX), an anti-CD20 chimerical monoclonal antibody, has been used as an off-label in patients with systemic lupus erythematosus (SLE) refractory to standard treatment.…Abstract Number: 674 • 2014 ACR/ARHP Annual Meeting
A Novel Strategy to Identify and Evaluate Approved Drugs and Treatments for Repositioning As Therapies for Systemic Lupus Erythematosus (SLE)
Background/Purpose: Development of new SLE treatments has been slow with only one new treatment approved in the past half century. One way to increase the…Abstract Number: 673 • 2014 ACR/ARHP Annual Meeting
A Comparison of Rheumatoid Arthritis and Systemic Lupus Erythematosus Trial Design: Ways to Improve Positive Trials in Systemic Lupus Erythematosus
Background/Purpose: Recent SLE RCTs were examined and compared to rheumatoid arthritis (RA) RCT to suggest modifications to SLE RCTs that could improve the future success…
ACR Meeting Abstracts